News | September 17, 2024
Wacker collaborates with MinervaX for prophylactic vaccine targeting Group B streptococcus
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Total investment incurred for setting up the new R&D Rs 250 crore
The USFDA inspection focused on evaluating the facility's adherence to global regulatory requirements and best practices
The acquisition is based on an enterprise value of Rs. 1,660 crore
Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
Stressed was on the need to promote organ donation from the deceased persons to meet the huge need for organ donation in the country
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
Subscribe To Our Newsletter & Stay Updated
